Targeting calcium transport in ischaemic heart disease

Cardiovascular Research

Volumn 84, Issue 3, 2009, Pages 345-352

  Talukder, M A Hassan ^a   Zweier, Jay L ^a,b   Periasamy, Muthu ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Ca2+ overload; Heart failure; Ischaemia reperfusion; Ischaemic myocardium

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; 2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALDARET; CARDIOVASCULAR AGENT; CARIPORIDE; DANTROLENE; ISTAROXIME; MCC 135; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SN 6; SODIUM PROTON EXCHANGE PROTEIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CALCIUM TRANSPORT; CARDIOMYOPATHY; CYTOSOL; EXCITATION CONTRACTION COUPLING; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL TRANSPORT; CALCIUM; CALCIUM CHANNELS, L-TYPE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-CALCIUM EXCHANGER;

EID: 70849109969     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp264     Document Type: Review

References (124)

1. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-2195. (Pubitemid 350123680)
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N et al. Heart disease and stroke statistics-2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
3. Gross GJ, Kersten JR, Warltier DC. Mechanisms of postischemic contractile dysfunction. Ann Thorac Surg 1999;68:1898-1904.
4. Piper HM, Garćia-Dorado D. Prime causes of rapid cardiomyocyte death during reperfusion. Ann Thorac Surg 1999;68:1913-1919.
5. Verma S, Fedak PW, Weisel RD, Butany J, Rao V, Maitland A et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002;105:2332-2336. (Pubitemid 34556381)
6. Woo KS, White HD. Factors affecting outcome after recovery from myo-cardial infarction. Annu Rev Med 1994;45:325-339.
7. Fleming PR. A Short History of Cardiology. Amsterdam/Atlanta, GA: Rodopi Publishers; 1997.
8. Saraste A, Nekolla S, Schwaiger M. Contrast-enhanced magnetic resonance imaging in the assessment of myocardial infraction and viability. J Nucl Cardiol 2008;15:105-117.
9. Van Der Werf JJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost 2009;7:14-20.
10. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. I: history and development. BMJ 2003;326:1080-1082.
11. Sellke F, Swanson S, del Nido PJ. Sabiston & Spencer Surgery of the Chest. Saunders, PA: Elsevier Health Sciences; 2004.
12. Heidenreich PA, McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Am J Med 2001;110:165-174.
13. Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW. How much of the recent decline in the incidence of myocar-dial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 2008;117:598-604.
14. Luepker RV. Decline in incident coronary heart disease. Why are the rates falling? Circulation 2008;117:592-593.
15. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. Myocar-dial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004;95:125-134.
16. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodeling. Nat Rev Mol Cell Biol 2003;4:517-529.
17. Elz JS, Nayler WG. Contractile recovery and reperfusion-induced calcium gain after ischemia in the isolated rat heart. Lab Invest 1988; 58:653-659.
18. Steenbergen C, Fralix TA, Murphy E. Role of increased cytosolic free calcium concentration in myocardial ischemic injury. Basic Res Cardiol 1993;88:456-470.
19. Siegmund B, Schlüter KD, Piper HM. Calcium and the oxygen paradox. Cardiovasc Res 1993;27:1778-1783.
20. Meissner A, Morgan JP. Contractile dysfunction and abnormal Ca2θ modulation during postischemic reperfusion in rat heart. Am J Physiol Heart Circ Physiol 1995;268:H100-H111.
21. Piper HM, Garćia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998;38:291-300.
22. Clarendon EH. The life of Edward, Earl of Clarendon. Oxford: Clarendon Press; 1759.
23. McNee JW. The clinical syndrome of thrombosis of the coronary arteries. Q J Med 1925;19:44-52.
24. Heberden W. Some account of a disorder of the breast. Med Trans R Coll Physicians (Lond) 1772;2:59-67.
25. Parry CS. An Inquiry into the Symptoms and Causes of the Syncope Angi-nosa, Commonly Called Angina Pectoris. Bath: R Crutwell; 1799.
26. Hunter J. A Treatise in Blood, Inflammation and Gun-shot Wounds to which is Prefixed a Short Account of the Author's Life by his Brother-in-law Everard Home. London: G Nichol; 1794.
27. Livesley B. The spasms of John Hunder: a new interpretation. Med Hist 1973;17:70-75.
28. Osler W. Lumleian lecture on angina pectoris. Lancet 1910;I:839-844.
29. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. J Am Med Assoc 1912;59:2015-2020.
30. Parkinson J, Bedford DE. Cardiac infarction and coronary thrombosis. Lancet 1928;1:4-11.
31. Lewis T. Diseases of the Heart. London: MacMillan; 1933.
32. Bers DM. Cardiac excitation-contraction coupling. Nature 2002;415: 198-205.
33. Zweier JL, Talukder MA. The role of oxidants and free radicals in reper-fusion injury. Cardiovasc Res 2006;70:181-190.
34. Zimmerman ANE, Daems W, Hulsmann WC, Snijder J, Wisse E, Durrier D. Morphological changes of heart muscle caused by successive perfusion with calcium-free and calcium-containing solutions (calcium paradox). Cardiovasc Res 1967;1:201-209.
35. Nayler WG. The role of calcium in the ischemic myocardium. Am J Pathol 1981;102:262-270.
36. Nayler WG, Perry SE, Elz JS, Daly MJ. Calcium, sodium and the calcium paradox. Circ Res 1984;55:227-237.
37. Poole-Wilson PA, Harding DP, Bourdillon PD, Tones MA. Calcium out of control. J Mol Cell Cardiol 1984;16:175-187.
38. Kusuoka H, Porterfield JK, Weisman HF, Weisfeldt ML, Marban E. Patho-physiology and pathogenesis of stunned myocardium. Depressed Ca2θ activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts. J Clin Invest 1987;79:950-961.
39. Opie LH. Role of calcium and other ions in reperfusion injury. Cardiovasc Drugs Ther 1991;5:237-248.
40. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-634.
41. Kim S-J, Depre C, Vatner SF. Novel mechanisms mediating stunned myocardium. Heart Fail Rev 2003;8:143-153.
42. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008;88:581-609.
43. Piper HM. The calcium paradox revisited: an artifact of great heuristic value. Cardiovasc Res 2000;45:123-127.
44. Bush LR, Romson JL, Ash JL, Lucchesi BR. Effect of diltiazem on extent of ultimate myocardial injury resulting from temporary coronary artery occlusion in dogs. J Cardiovasc Pharmacol 1982;4:285-296.
45. Lamping KA, Gross GJ. Improved recovery of myocardial segment function following a short-coronary occlusion in dogs by nicorandil, a potential new antianginal agent, and nifedipine. J Cardiovasc Pharmacol 1985;7:158-166.
46. Przyklenk K, Ghafari GB, Eitzman DT, Kloner RA. Nifedipine administered after reperfusion ablates systolic contractile dysfunction of post-ischemic 'stunned' myocardium. J Am Coll Cardiol 1989;13:1176-1183.
47. Gross GJ, Farber NE, Pieper NE. Effects of amlodipine on myocardial ischemia-reperfusion injury in dogs. Am J Cardiol 1989;64:94I-100I.
48. duToit EF, Opie LH. Modulation of severity of reperfusion stunning in the isolated rat hearts by the agents altering calcium flux at the onset of reperfusion. Circ Res 1992 70 960-967.
49. Hoff PT, Tamura Y, Lucchesi BR. Cardioprotective effects of amlodipine in the ischemic-reperfused heart. Am J Cardiol 1989;64:101I-115I.
50. Garćia-Dorado D, Theroux P, Fernandez-Aviles F, Elizaga J, Solares J, Galinanes M. Diltiazem and progression of myocardial ischemic damage during coronary artery occlusion and reperfusion in porcine hearts. J Am Coll Cardiol 1987;10:906-911.
51. Bersohn MM, Morey AK, Weiss RS. Sarcolemmal calcium transporters in myocardial ischemia. J Mol Cell Cardiol 1997;29:2525-2532.
52. Zucchi R, Ronca-Testoni S, Yu G, Galbani P, Ronca G, Mariani M. Are dihy-dropyridine receptors downregulated in the ischemic myocardium? Car-diovasc Res 1995;30:769-774.
53. Sallinen P, Mänttäri S, Leskinen H, Ilves M, Ruskoaho H, Saarela S. Time course of changes in the expression of DHPR, RyR2, and SERCA2 after myocardial infarction in the rat left ventricle. Mol Cell Biochem 2007; 303:97-103.
54. The HINT Research Group. Early treatment of unstable angina in the coronary care unit, a randomized, double-blind placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986;56:400-413.
55. Theroux P, Gregoire J, Chin C, Pelletier G, de Guise P, Juneau M. Intravenous diltiazem in acute myocardial infarction. DATA trial. J Am Coll Cardiol 1998;32:620-628.
56. Sheiban I, Tonni S, Chizzoni A, Marini A, Trevi G. Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. Cardiovasc Drugs Ther 1997;11:5-16.
57. Misquitta CM, Mack DP, Grover AK. Sarco/endoplasmic reticulum Ca2θ (SERCA)-pumps: link to heart beats and calcium waves. Cell Calcium 1999;25:277-290.
58. Periasamy M, Huke S. SERCA pump level is a critical determinant of Ca(2θ)homeostasis and cardiac contractility. J Mol Cell Cardiol 2001; 33:1053-1063.
59. Frank KF, Bolck B, Erdmann E, Schwinger RH. Sarcoplasmic reticulum Ca2θ-ATPase modulates cardiac contraction and relaxation. Cardiovasc Res 2003;57:20-27.
60. Lee KS, Ladinsky H, Stuckey JH. Decreased Ca2θ uptake by sarcoplasmic reticulum after coronary artery occlusion for 60 and 90 min. Circ Res 1967;21:439-444.
61. Toba K, Katagiri T, Takeyama Y. Studies of the sarcoplasmic reticulum in myocardial infarction. Jpn Circ J 1978;42:447-453.
62. Krause S, Hess ML. Characterization of cardiac sarcoplasmic reticulum dysfunction during short-term, normothermic, global ischemia. Circ Res 1984;55:176-184.
63. Kaplan P, Hendrikx M, Mattheussen M, Mubagwa K, Flameng W. Effect of ischemia and reperfusion on sarcoplasmic reticulum calcium uptake. Circ Res 1992;71:1123-1130.
64. Mubagwa K. Sarcoplasmic reticulum function during myocardial ischae-mia and reperfusion. Cardiovasc Res 1995;30:166-175.
65. Zucchi R, Ronca-Testoni S, Di Napoli P, Yu G, Gallina S, Bosco G et al. Sarcoplasmic retciculum calcium uptake in human myocardium subjected to ischemia and reperfusion during cardiac surgery. J Mol Cell Cardiol 1996;28:1693-1701.
66. del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, Gwathmey JK et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci USA 2004;101:5622-5627.
67. Niwano K, Arai M, Koitabashi N, Watanabe A, Ikeda Y, Miyoshi H et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther 2008;16:1026-1032.
68. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000;97:793-798.
69. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008;15:1550-1557.
70. Talukder MA, Kalyanasundaram A, Zuo L, Velayutham M, Nishijima Y, Periasamy M et al. Is reduced SERCA2a expression detrimental or beneficial to postischemic cardiac function and injury? Evidence from heterozygous SERCA2a knockout mice. Am J Physiol Heart Circ Physiol 2008;294:H1426-H1434.
71. Talukder MA, Yang F, Nishijima Y, Chen CA, Kalyanasundaram A, Periasamy M et al. Reduced SERCA2a converts sub-lethal myocardial injury to infarction and affects postischemic functional recovery. J Mol Cell Cardiol 2009;46:285-287.
72. Talukder MA, Kalyanasundaram A, Xue Z, Zuo L, Bhupathy P, Babu GJ et al. Expression of SERCA isoform with faster Ca2θ transport properties improves postischemic cardiac function, Ca2θ handling, and decreases myocardial infarction. Am J Physiol Heart Circ Physiol 2007;293: H1418-H1428.
73. Piper HM, Kasseckert S, Abdallah Y. The sarcoplasmic reticulum as the primary target of reperfusion protection. Cardiovasc Res 2006;70: 170-173.
74. Teucher N, Prestle J, Seidler T, Currie S, Elliott EB, Reynolds DF et al. Excessive sarcoplasmic/endoplasmic reticulum Ca2θ-ATPase expression causes increased sarcoplasmic reticulum Ca2θ uptake but decreases myocyte shortening. Circulation 2004;110:3553-3559.
75. Chen Y, Escoubet B, Prunier F, Amour J, Simonides WS, Vivien B et al. Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reti-culum Ca2θ-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation 2004;109:1898-1903.
76. Northover BJ. Effects of pretreatment with caffeine or ryanodine on the myocardial response to simulated ischaemia. Br J Pharmacol 1991;103: 1225-1229.
77. Du Toit EF, Opie LH. Modulation of severity of reperfusion stunning in isolated rat heart by agents altering calcium flux at onset of reperfusion. Circ Res 1992;70:960-970.
78. Mubagwa K, Kaplan P, Flameng W. The effects of ryanodine on calcium uptake by the sarcoplasmic reticulum of ischemic and reperfused rat myocardium. Fundam Clin Pharmacol 1997;11:315-321.
79. Zucchi R, Ronca-Testoni S. The sarcoplasmic reticulum Ca2θ channel/ ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev 1997;49:1-51.
80. Zucchi R, Ronca-Testoni S, Yu G, Galbani P, Ronca G, Mariani M. Effect of ischemia and reperfusion on cardiac ryanodine receptors-sarcoplasmic reticulum Ca2θ channels. Circ Res 1994;74:271-280.
81. Valdivia C, Hegge JO, Lasley RD, Valdivia HH, Mentzer R. Ryanodine receptor dysfunction in porcine stunned myocardium. Am J Physiol Heart Circ Physiol 1997;273:H796-H804.
82. Xu Y-J, Chapman D, Dixon IMC, Sethi R, Guo X, Dhalla NS. Differential gene expression in infarct scar and viable myocardium from rat heart following coronary ligation. J Cell Mol Med 2004;8:85-92.
83. Dixon IM, Kaneko M, Hata T, Panagia V, Dhalla NS. Alterations in cardiac membrane Ca2θ transport during oxidative stress. Mol Cell Biochem 1990;99:125-133.
84. Zima AV, Blatter LA. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006;71:310-321.
85. Cherednichenko G, Zima AV, Feng W, Schaefer S, Blatter LA, Pessah IN. NADH oxidase activity of rat cardiac sarcoplasmic reticulum regulates calcium-induced calcium release. Circ Res 2004;94:478-486.
86. Blaustein M, Lederer J. Sodium/calcium exchange: its physiological implications. Physiol Rev 1999;79:763-854.
87. Tani M, Neely JR. Role of intracellular Naθ in Ca2θ overload and depressed recovery in ventricular function of reperfused ischemic rat hearts. Possible involvement of Hθ-Naθ and Naθ-Ca2θ exchange. Circ Res 1989;65:1045-1056.
88. Cross HR, Lu L, Steenbergen C, Philipson KD, Murphy E. Overexpression of the cardiac Naθ/Ca2θ exchanger increases susceptibility to ischemia/ reperfusion in male, but not female, transgenic mice. Circ Res 1998;83: 1215-1223.
89. Ohtsuka M, Takano H, Suzuki M, Zou Y, Akazawa H, Tamagawa M et al. Role of Naθ-Ca2θ exchanger in myocardial ischemia/reperfusion injury: evaluation using a heterozygous Naθ-Ca2θ exchanger knockout mouse model. Biochem Biophys Res Commun 2004;314:849-853.
90. Imahashi K, Christian P, Goldhaber JI, Steenberger C, Philipson KD, Murphy E. Cardiac-specific ablation of the Naθ-Ca2θ exchanger confers protection against ischemia/reperfusion injury. Circ Res 2005;97: 916-921.
91. Inserte J, Garcia-Dorado D, Ruiz-Meana M, Padilla F, Barrabés JA, Pina P et al. Effect of inhibition of the Naθ/ C a 2θ exchanger at the time of myocardial reperfusion on hypercontracture and cell death. Cardiovasc Res 2002;55:739-748.
92. Karmazyn M, Gan XT, Humphrevs RA, Yoshida H, Kusumoto K. The myo-cardial Na(θ)-H(θ) exchange: structure, regulation, and its role in heart disease. Circ Res 1999;85:777-786.
93. Karmazyn M. Amiloride enhances postischemic ventricular recovery: possible role of Naθ-Hθ exchange. Am J Physiol Heart Circ Physiol 1988;255:H608-H615.
94. Levitsky J, Gurell D, Frishman WH. Sodium ion/hydrogen ion inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. J Clin Pharmacol 1998;38:887-897.
95. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4:566-577.
96. Schoutsen B, Blom JJ, Verdouw PD, Lamers JM. Calcium transport and phospholamban in sarcoplasmic reticulum of ischemic myocardium. J Mol Cell Cardiol 1989;21:719-727.
97. Vittone L, Mundina-Weilenmann C, Mattiazzi A. Phospholamban phos-phorylation by CaMKII under pathophysiological conditions. Front Biosci 2008;13:5988-6005.
98. Weber T, Neumann J, Meißner A, Hartlage MG, Aken HV, Hanske G et al. Reduced serine-16 and threonine-17 phospholamban phosphorylation in stunning of conscious dogs. No evidence for any involvement of protein kinase A or protein phosphatases. Basic Res Cardiol 2006;101:253-260.
99. Cross HR, Kranias EG, Murphy E, Steenbergen C. Ablation of PLB exacerbates ischemic injury to a lesser extent in female than male mice: protective role of NO. Am J Physiol Heart Circ Physiol 2003;284: H683-H690.
100. Maier LS, Bers DM. Role of Ca2θ/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. Cardiovasc Res 2007;73:631-640.
101. Anderson ME. Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther 2005;106:39-55.
102. Couchonnal LF, Anderson ME. The role of calmodulin kinase II in myocar-dial physiology and disease. Physiol 2008;23:151-159.
103. Vila-Petroff M, Salas MA, Said M, Valverde CA, Sapia L, Portiansky E et al. CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion. Cardiovasc Res 2007;73:689-698.
104. Currie S, Smith GL. Calcium/calmodulin-dependent protein kinase II activity is increased in sarcoplasmic reticulum from coronary artery ligated rabbit hearts. FEBS Lett 1999;459:244-248.
105. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJGM. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007;74:343-355.
106. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/ reperfusion-injury, a clinical view on a complex pathophysiological process. Intl J Cardiol 2005;100:179-190.
107. Wang Q-D, Pernow J, Sjöquist P-O, Rydén L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 2002;55:25-37.
108. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol 2004;44: 276-286.
109. Wijeysundera DN, Beattie WS, Rao V, Karski J. Calcium antagonist reduce cardiovascular complications after cardiac surgery: a meta-analysis. J Am Coll Cardiol 2003;41:1496-1505.
110. Costanzo P, Perrone-Filardi P, Petretta M, Marciano C, Vassallo E, Gargiulo P et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175634 patients. J Hypertens 2009;27: 1136-1151.
111. Zucchi R, Ronca F, Ronca-Testoni S. Modulation of sarcoplasmic reticu-lum function: a new strategy in cardioprotection? Pharmacol Ther 2001;89:47-65.
112. Vangheluwe P, Sipido KR, Raeymaekers L, Wuytack F. New perspectives on the role of SERCA2's Ca2θ affinity in cardiac function. Biochim Biophys Acta 2006;1763:1216-1228.
113. Ghali JK, Smith WB, Torre-Amione G, Haynos W, Rayburn BK, Amato A et al. A phase 1-2 dose-escalating study evaluating the safety and toler-ability of Istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 2007;99(suppl.):47A-56A.
114. Micheletti R, Palazzo F, Barassi P, Giacalone G, Ferrandi M, Schiavone A et al. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adeno-sine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol 2007;99(suppl.):24A-32A.
115. Yu G, Zucchi R, Ronca-Testoni S, Ronca G. Protection of ischemic rat heart by dantrolene, an antagonist of the sarcoplasmic reticulum calcium release channel. Basic Res Cardiol 2000;95:137-143.
116. Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmaco-dynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986;32:130-168.
117. Koehntop DE, Beebe DS, Belani KG. The safety of dantrolene in a patient with severe cardiomyopathy requiring a heart transplant. Anesth Analg 1997;85:229-230.
118. Lee C, Dhalla NS, Hryshko LV. Therapeutic potential of novel Naθ-Ca2θ exchange inhibitors in attenuating ischemia-reperfusion injury. Can J Cardiol 2005;21:509-516.
119. Karmazyn M. Pharmacology and clinical assessment of cariporide for the treatment coronary artery disease. Exp Opin Invest Drugs 2000;9: 1099-1108.
120. Avkiran M, Marber MS. Naθ/Hθ exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J Am Coll Cardiol 2002;39: 747-753.
121. Murphy E, Allen DG. Why did the NHE inhibitor clinical trial fail? J Mol Cell Cardiol 2009;46:137-141.
122. Mentzer RM, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 2008;85: 1261-1270.
123. Jang I-K, Pettigrew V, Picard MH, Kowey PR, Demmel V, Zile MR et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis 2005;20: 147-153.
124. Tzivoni D, Balkin J, B̈ar FW, Hibberd M, Reiber JHC, Cowing G. Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2009;103:1-4.